The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula ##STR00001## a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C.sub.1-10alkanediyl; R.sup.1 is Ar.sup.1 or a monocyclic or bicyclic heterocycle Q is R.sup.7, pyrrolidinyl substituted with R.sup.7, piperidinyl substituted with R.sup.7 or homopiperidinyl substituted with R.sup.7; one of R.sup.2a and R.sup.3a is selected from halo, optionally mono- or polysubstituted C.sub.1-6alkyl, optionally mono- or polysubstituted C.sub.2-6alkenyl, nitro, hydroxy, Ar.sup.2, N(R.sup.4aR.sup.4b), N(R.sup.4aR.sup.4b)sulfonyl, N(R.sup.4aR.sup.4b)carbonyl, C.sub.1-6alkyloxy, Ar.sup.2oxy, Ar.sup.2C.sub.1-6alkyloxy, carboxyl, C.sub.1-6alkyloxycarbonyl, or --C(=Z)Ar.sup.2; and the other one of R.sup.2a and R.sup.3a is hydrogen; in case R.sup.2a is different from hydrogen then R.sup.2b is hydrogen, C.sub.1-6alkyl or halogen and R.sup.3b is hydrogen; in case R.sup.3a is different from hydrogen then R.sup.3b is hydrogen, C.sub.1-6alkyl or halogen and R.sup.2b is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.
This application is a National Stage application under 35 U.S.C. 371 of Application No. PCT/EP2004/053620 filed Dec. 20, 2004, which claims priority from European Patent Application No. EP03104810.1 filed Dec. 18, 2003, European Patent Application No. EP04105312.5 filed Oct. 26, 2004, and U.S. Provisional Application No. 60/567 182 filed Apr. 30, 2004, the contents of all of which are hereby incorporated by reference.
Priority Data
Dec 18, 2003 [EP] 03104810 Oct 26, 2004 [EP] 04105312
